Montara Launches MT1110 Drug, Clinical Trials Set for H2 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Globenewswire
- Major Milestone: Montara announces its first development candidate MT1110 from the BrainOnly platform, aimed at treating TSC-related epilepsy and other CNS diseases in combination with everolimus, with clinical trials expected to start in H2 2026, marking a significant advancement in neurological drug development.
- Innovative Drug Combination: The MT1110-everolimus combination demonstrated superior seizure control in mouse models compared to everolimus alone, reducing adverse effects and indicating potential to enhance efficacy and safety, which could transform treatment options for TSC patients.
- Strategic Collaboration: Montara's partnership with TSC Alliance and Psychogenics showcases initial preclinical data emphasizing MT1110's advantages, further advancing the company's R&D efforts in CNS diseases and enhancing its competitive position in the market.
- Executive Appointment: Dr. Jeremy Grunstein has been appointed as Chief Business Officer to drive strategic partnerships for MT1110 with other CNS-targeted drugs, and his extensive experience in the biopharmaceutical industry is expected to accelerate Montara's commercialization efforts and strengthen its market position.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
